Literature DB >> 3964531

Dose independent pharmacokinetics of mexiletine in healthy volunteers.

T Pringle, J Fox, J A McNeill, C D Kinney, J Liddle, D W Harron, R G Shanks.   

Abstract

In 12 healthy volunteers who received orally 100, 200, 300, 400 and 600 mg mexiletine at weekly intervals, the maximum plasma concentration of mexiletine and AUC increased linearly with the dose of mexiletine. Between doses there were no significant differences in the values for clearance and volume of distribution of mexiletine but there were for plasma elimination half-life. These results indicate that the kinetics of mexiletine are linear.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3964531      PMCID: PMC1400855          DOI: 10.1111/j.1365-2125.1986.tb05196.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  The distribution, metabolism and excretion of mexiletine in man.

Authors:  A H Beckett; E C Chidomere
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Dose-dependent pharmacokinetics of aprindine in healthy volunteers.

Authors:  T Kobari; T Itoh; T Hirakawa; H Namekawa; T Suzuki; T Satoh; N Iida; F Ohtsu; H Hayakawa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

Review 5.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

6.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

  6 in total
  5 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 4.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 5.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.